Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

The weakness was also weighing on shares of some of Walmart's rivals, as Costco Wholesale Corp.'s stock (COST) fell 2.2% and Target Corp. shares (TGT) shed 1.1%, to underperform the S&P 500 index's ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.